AbbVie Inc. (ABBV) operating KPIs
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$294.89+4.10 (+1.41%)
Close on Oct 30, 2026Market cap $521.11BP/E 83.3Yield 2.26%
AbbVie restructuring Reserve Liability [legacy through FY20Q1] ($M) ($M)
Form 10-Q / 10-K Restructuring Note
Latest, FY2019
140
Period ended Dec 31, 2019
Change on a year earlier
+41.4%
99 in FY2018
History
5 years
Since FY2015
Sources
3
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Restructuring Reserve Liability [legacy through FY20Q1] ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2019 | Dec 31, 2019 | 140 | +41.4% | Form 10-Q (filed 2020-05-08) ↗ |
| FY2018 | Dec 31, 2018 | 99 | +15.1% | Form 10-K (filed 2020-02-21) ↗ |
| FY2017 | Dec 31, 2017 | 86 | -1.1% | Form 10-K (filed 2020-02-21) ↗ |
| FY2016 | Dec 31, 2016 | 87 | -41.2% | Form 10-K (filed 2020-02-21) ↗ |
| FY2015 | Dec 31, 2015 | 148 | – | Form 10-K (filed 2019-02-27) ↗ |
Cite this data
StockData. (2026). AbbVie Restructuring Reserve Liability [legacy through FY20Q1] ($M) ($M), annual FY2015–FY2019 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/restruct_res_leg
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.